Compare Sezzle Inc (SEZL) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sezzle Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Sezzle Inc trades at $122.66 (market cap $4.39B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is the larger of the two by market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Sezzle Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Sezzle Inc for 15 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| SEZL | SYRE | |
|---|---|---|
Market Cap | $4.39B | $7.52B |
Volume | 424,843 | 1,441,031 |
Sector | Financials | Health |
52-Week High | $188.55 | $108.92 |
52-Week Low | $50.97 | $22.18 |
Typical Hold Time | 15 Days | 0 Days |
Enterprise Value | $4.44B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sezzle (SEZL) trades at $130.05, down 0.33% today, with a bullish technical signal and strong support near $127. The company demonstrates robust fundamentals, with Q2 2026 revenue growth of 51.7% year-over-year and a net income margin of 30.35%. Recent product launches like Sezzle Send and SezzleCash are driving user growth, while analyst consensus remains positive with a $168 price target.
Outlook is favorable given sustained earnings beats and raised guidance, but risks include competitive pressures in the BNPL sector and elevated valuation multiples. The stock offers growth potential if execution continues, though overbought technical indicators suggest near-term volatility.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Sezzle Inc
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
